All In Biotech

Drug Trial Radar · NCT06106009

A Study to Learn How Different Amounts of the Study Medicine Called PF-07976016 Are Tolerated and Act in The Body in Healthy Adults

A Multi-Part, Phase 1 Study With Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Single- And Multiple-Dose Escalation To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-07976016 In Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: Sep 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 117 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

117

Actual

Start

Oct 27, 2023

Primary completion

Aug 19, 2024

Study completion Aug 19, 2024

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Oct 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to learn if the study medicine (called PF-07976016) is safe and how it goes in and out of the body in healthy people. The study may also explore if PF-07976016 has the potential to interact with another medicine called midazolam. In addition, the study may explore how PF-07976016 goes into the body of people who have obesity.

Conditions

  • Healthy

Interventions

  • PF-07976016Drug

    Oral solution, oral suspension or solid oral formulation(s)

  • PlaceboDrug

    Oral solution, oral suspension or solid oral formulation(s)

  • MidazolamDrug

    Midazolam oral solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Number of Participants With Treatment Emergent Adverse Events Following Single DosesTime frame: Day 1 up to approximately Day 36
  2. Part A: Number of Participants With Clinical Laboratory Abnormalities Following Single DosesTime frame: Day 1 up to approximately Day 36
  3. Part A: Number of Participants With Clinically Significant Change in Baseline Vital Signs Following Single DosesTime frame: Day 1 up to approximately Day 36
  4. Part A: Number of Participants With Clinically Significant Change from Baseline in Electrocardiogram Findings Following Single DosesTime frame: Day 1 up to approximately Day 36
  5. Part B, Parts C and D, if conducted: Number of Participants With Treatment Emergent Adverse Events Following Multiple DosesTime frame: Day 1 up to approximately Day 49
  6. Part B, Parts C and D, if conducted: Number of Participants With Clinical Laboratory Abnormalities Following Multiple DosesTime frame: Day 1 up to approximately Day 49
  7. Part B, Parts C and D, if conducted: Number of Participants With Clinically Significant Change in Baseline Vital Signs Following Multiple DosesTime frame: Day 1 up to approximately Day 49
  8. Part B, Parts C and D, if conducted: Number of Participants With Clinically Significant Change from Baseline in Electrocardiogram Findings Following Multiple DosesTime frame: Day 1 up to approximately Day 49

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pfizer Clinical Research Unit - New Haven

    New Haven, Connecticut

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.